AbbVie (ABBV) IV into FDA decision on Rinvoq
Tweet
Share
E-mail
Get Alerts ABBV Hot Sheet
Join SI Premium – FREE
AbbVie (NYSE: ABBV) 30-day option implied volatility is at 23; compared to its 52-week range of 18 to 40 into FDA decision on Rinvoq.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbvie (ABBV) PT Raised to $288 at Guggenheim
- FDA accepts AbbVie's Botox Cosmetic application for jaw slimming use
- Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
Create E-mail Alert Related Categories
OptionsRelated Entities
Options, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
